Method for automated generation of genetically modified T cells

Patent metadata

Field	Value
Publication number	US-10131876-B2
Application number	US-201515305597-A
Country	US
Kind code	B2
Filing date	Apr 23, 2015
Priority date	Apr 24, 2014
Publication date	Nov 20, 2018
Grant date	Nov 20, 2018

Abstract

The present invention provides a process for generation of genetically modified T cells, T cell subsets and/or T cell progenitors comprising the steps: a) providing a cell sample comprising T cells, T cell subsets and/or T cell progenitors b) preparation of the cell sample by centrifugation c) magnetic separation of the T cells, T cell subsets and/or T cell progenitors d) activation of the enriched T cells, T cell subsets and/or T cell progenitors using modulatory agents e) genetic modification of the T cells, T cell subsets and/or T cell progenitors f) expansion of the genetically modified T cells, T cell subsets and/or T cell progenitors in a cultivation chamber g) washing of the cultured T cells, T cell subsets and/or T cell progenitors characterized in that all steps are performed in a closed and sterile cell culture system.

First claim

The invention claimed is:

1. A process for generation of genetically modified T cells, T cell subsets and/or T cell progenitors comprising the steps:
a) providing a cell sample comprising T cells, T cell subsets and/or T cell progenitors;
b) preparation of the cell sample by centrifugation;
c) magnetic separation of the T cells, T cell subsets and/or T cell progenitors, to thereby provide enriched T cells, T cell subsets and/or T cell progenitors;
d) activation of the enriched T cells, T cell subsets and/or T cell progenitors using modulatory agents, to thereby provide activated T cells, T cell subsets and/or T cell progenitors;
e) genetic modification of the activated T cells, T cell subsets and/or T cell progenitors, to thereby provide genetically modified T cells, T cell subsets and/or T cell progenitors; and
f) expansion of the genetically modified T cells, T cell subsets and/or T cell progenitors in a cultivation chamber, to thereby provide cultured T cells, T cell subsets and/or T cell progenitors; and
g) washing of the cultured T cells, T cell subsets and/or T cell progenitors, characterized in that all steps are performed within a closed and sterile cell culture system, and wherein expansion step (f) is performed under shaking conditions.

2. The process according to claim 1 , wherein activation is performed using T cell, T cell subsets and/or T cell progenitor densities from between 0.5e 6 cells/mL to 4e 6 cells/mL during activation.

3. The process according to claim 1 , wherein activation is performed using high T cell, T cell subsets and/or T cell progenitor densities from between 4e 6 cells/mL to 1e 7 cells/mL during activation.

4. The process according to claim 1 , wherein genetic modification comprises introducing into the activated T cells, T cell subsets and/or T cell progenitors a polynucleotide sequence encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR).

5. A process for generation of genetically modified T cells, T cell subsets and/or T cell progenitors comprising the steps:
a) providing a cell sample comprising T cells, T cell subsets and/or T cell progenitors
b) preparation of the cell sample by centrifugation;
c) magnetic separation of the T cells, T cell subsets and/or T cell progenitors, to thereby provide enriched T cells, T cell subsets and/or T cell progenitors;
d) activation of the enriched T cells, T cell subsets and/or T cell progenitors using modulatory agents, to thereby provide activated T cells, T cell subsets and/or T cell progenitors;
e) genetic modification of the activated T cells, T cell subsets and/or T cell progenitors, to thereby provide genetically modified T cells, T cell subsets and/or T cell progenitors, wherein the genetic modification is a polynucleotide sequence encoding for a chimeric antigen receptor (CAR) or a T cell receptor (TCR), and wherein the genetically modified T cells, T cell subsets and/or T cell progenitors express the CAR or the TCR;
f) expansion of the genetically modified T cells, T cell subsets and/or T cell progenitors in a cultivation chamber, to thereby provide cultured T cells, T cell subsets and/or T cell progenitors; and
g) washing the cultured T cells, T cell subsets and/or T cell progenitors, wherein all steps are performed within a closed and sterile cell culture system, and wherein the genetically modified cells expressing the CAR or the TCR are separated from cells not expressing the CAR or the TCR in an additional magnetic separation step before step (g) is performed.

6. The process according to claim 1 , wherein the modulatory agents are selected from the group consisting of: agonistic antibodies, cytokines, recombinant costimulatory molecules and small drug inhibitors.

7. The process according to claim 1 , wherein the modulatory agents are anti-CD3 and anti-CD28 antibodies or fragments thereof coupled to beads or nanostructures.

8. The process according to claim 7 , wherein the nanostructures are nanomatrices, wherein the nanomatrices comprise a matrix of mobile polymer chains attached to anti-CD3 and anti-CD28 antibodies or fragments thereof, and wherein the nanomatrices are 1 to 500 nm in size.

9. The process according to claim 1 , wherein genetic modification is performed by transducing the activated T cells, T cell subsets and/or T cell progenitors with lentiviruses, gamma-retroviruses, alpha-retroviruses or adenoviruses, by electroporation, or by transfection of nucleic acids, proteins, site-specific nucleases, self-replicating RNA viruses or integration-deficient lentiviral vectors.

10. The process according to claim 1 , wherein the genetic modification of T cells, T cell subsets and/or T cell progenitors is performed by transducing the activated T cells, T cell subsets and/or T cell progenitors with lentiviral vectors.

11. The process according to claim 1 , wherein the magnetic separation of the T cells, T cell subsets and/or T cell progenitors is performed using antigen-binding molecules specific for a cell surface marker on the surface of the T cells, T cell subsets and/or T cell progenitors and coupled to magnetic particles.

12. The process of claim 11 , wherein the cell surface marker is selected from the group consisting: CD2, CD3, CD4, CD8 CD25, CD28, CD27, CD45RA, CD45RO, CD62L, CD95, CD127, CD137, alpha/beta TCR, gamma/delta TCR, CCR7, PD-1 and Lag3.

13. The process according to claim 5 , wherein the modulatory agents are selected from the group consisting of: agonistic antibodies, cytokines, recombinant costimulatory molecules and small drug inhibitors.

14. The process according to claim 5 , wherein the genetic modification is performed by transducing the activated T cells, T cell subsets and/or T cell progenitors with lentiviruses, gamma-retroviruses, alpha-retroviruses or adenoviruses, by electroporation, or by transfection of nucleic acids, proteins, site-specific nucleases, self-replicating RNA viruses or integration-deficient lentiviral vectors.

15. The process according to claim 5 , wherein the activation is performed using T cell, T cell subsets and/or T cell progenitor densities from between 0.5e 6 cells/mL to 4e 6 cells/mL during activation.

16. The process according to claim 5 , wherein the activation is performed using high T cell, T cell subsets and/or T cell progenitor densities from between 4e 6 cells/mL to 1e 7 cells/mL during activation.

Assignees

• Miltenyi Biotec Gmbh

Inventors

• Kaiser Andrew
• Assenmacher Mario
• Johnston Ian

Classifications

• C07K14/7051 Primary

  T-cell receptor (TcR)-CD3 complex · CPC title

• C12N2501/51

  B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand) · CPC title

• C12N2510/00

  Genetically modified cells · CPC title

• C07K2319/00

  Fusion polypeptide · CPC title

• C12N5/0087

  Purging against subsets of blood cells, e.g. purging alloreactive T cells · CPC title